Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer

Recent Patents on Food, Nutrition and Agriculture

Volumn 2, Issue 1, 2010, Pages 12-55

  Yap, Kevin Yi Lwern ^a   See, Cheng Shang ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anticancer drugs; Chemotherapy; Complementary and alternative medicines; Herb drug interactions; Traditional Chinese medicine

Indexed keywords

ANTINEOPLASTIC AGENT;

ALTERNATIVE MEDICINE; ARTICLE; CHINESE MEDICINE; HERB DRUG INTERACTION; HUMAN; MEDICINAL PLANT; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATENT;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; HERB-DRUG INTERACTIONS; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; PATENTS AS TOPIC; PLANTS, MEDICINAL;

EID: 77957936260     PISSN: 22127984     EISSN: 18761429     Source Type: Journal    
DOI: 10.2174/1876142911002010012     Document Type: Review

References (305)

1. American Cancer Society. Cancer facts and figures 2008. http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf [Accessed 8 August 2009].
2. Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. http://www.cancer.org/downloads/STT/Global-Facts-and-Figures-2007-rev2.pdf [Accessed 8 August 2009].
3. Boon HS, Olatunde F, Zick SM. Trends in complementary/alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005. BMC Womens Health 2007;7:4.
4. Bressler R. Herb-drug interactions: interactions between kava and prescription medications. Geriatrics 2005;60(9):24-25. (Pubitemid 41318296)
5. Hyodo I, Amano N, Eguchi K, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23(12):2645-2654. (Pubitemid 46179453)
6. Chang L-C, Li I-C. Patterns of complementary therapy use by homebound cancer patients in Taiwan. Appl Nurs Res 2004;17(1):41-47. (Pubitemid 38251341)
7. Lim MK, Sadarangani P, Chan HL, Heng JY. Complementary and alternative medicine use in multiracial Singapore. Complement Ther Med 2005;13(1):16-24. (Pubitemid 40674262)
8. Lim J, Wong M, Chan MY, et al. Use of complementary and alternative medicine in paediatric oncology patients in Singapore. Ann Acad Med Singapore 2006;35(11):753-758. (Pubitemid 46045340)
9. Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. Cancer J 2006;12(5):425-431. (Pubitemid 44564825)
10. Yates JS, Mustian KM, Morrow GR, et al. Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 2005;13(10):806-811. (Pubitemid 41414021)
11. Vickers AJ, Cassileth BR. Unconventional therapies for cancer and cancer-related symptoms. Lancet Oncol 2001;2(4):226-232. (Pubitemid 33585935)
12. Kosty MP. PC-SPES: Hope or hype? J Clin Oncol 2004;22(18):3657-3659. (Pubitemid 41095203)
13. Siddiqui IA, Adhami VM, Saleem M, Mukhtar H. Beneficial effects of tea and its polyphenols against prostate cancer. Mol Nutr Food Res 2006;50(2):130-143. (Pubitemid 43325654)
14. Tasaki K, Maskarinec G, Shumay DM, Tatsumura Y, Kakai H. Communication between physicians and cancer patients about complementary and alternative medicine: Exploring patients' erspectives. Psychooncology 2002;11(3):212-220. (Pubitemid 34618586)
15. Kinsel JF, Straus SE. Complementary and alternative therapeutics: Rigorous research is needed to support claims. Annu Rev Pharmacol Toxicol 2003;43:463-484. (Pubitemid 37372650)
16. Kuhlmann J, Mück W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 2001;24(10):715-725. (Pubitemid 32848351)
17. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158(20):2200-2211. (Pubitemid 28512494)
18. Yap KY-L, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 2008;30(8):1385-1407.
19. Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6(7):546-558. (Pubitemid 43980543)
20. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-1221. (Pubitemid 34177427)
21. ® (rituximab) solution for infusion [package insert]. South San Francisco, CA, 2007.
22. rd ed. London, UK: BMJ Publishing Group Ltd & RPS Publishing 2007.
23. BC Cancer Agency. BCCA cancer drug manual. http://www.bccancer.bc.ca/HPI/ DrugDatabase/default.htm. [Accessed 8 August 2009].
24. th ed. Hudson, OH: Lexi-comp Inc. 2007-2008.
25. th ed. Hudson, Ohio: Lexi-comp 2007.
26. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenomics J 2001;1(3):167-170. (Pubitemid 33756654)
27. Chang H-M, But PP-H, Yao S-C, Wang L-L, Yeung SC-S. Pharmacology and applications of Chinese materia medica. Singapore: World Scientific Publishing Co. 2001.
28. Aetna InteliHealth Inc. Index of herbal medicines and supplements. http://www.intelihealth.com/IH/ihtIH/WSIHW000/8513/31402.html [Accessed 8 August 2009].
29. e-MS Inc. TCM Assistant. http://www.tcmassistant.com/index.html [Accessed 8 August 2009].
30. Gerstner Jr. LV. Memorial Sloan-Kettering Cancer Center - cancer information (about herbs, botanicals and other products). http://www.mskcc.org/ mskcc/html/11570.cfm [Accessed 8 August 2009].
31. ® Healthcare Series (version 5.1) [intranet database]. http://www.thomsonhc.com/hcs/librarian/PFPUI/ fV1mNyY303TXxR [Accessed 8 August 2009].
32. th ed. Stockton, CA: Therapeutic Research Faculty 2007.
33. ™: drug information online. http://www.drugs.com [Accessed 8 August 2009].
34. Gold Standard Inc. Caremark Drug Interactions. http://cpref.gsm.com/ inter.asp?r=8084 [Accessed 8 August 2009].
35. Enhanced Medical Decisions Inc. DoublecheckMD.comTM. http://www. doublecheckmd.com [Accessed 8 August 2009].
36. United States Patent and Trademark Office (USPTO). http://www.uspto.gov/ [Accessed 23 September 2009].
37. United States Patent and Trademark Office (USPTO). USPTO patent full-text and image database. http://patft.uspto.gov/netahtml/PTO/search-bool.html [Accessed 23 September 2009].
38. ®. http://ep. espacenet.com/[Accessed 23 September 2009].
39. FreePatentsOnline: all the inventions of mankind. http://www. freepatentsonline.com/[Accessed 23 September 2009].
40. Google Patents Beta. http://www.google.com/patents [Accessed 23 September 2009].
41. Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto DJ. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 1983;43(11):5151-5155. (Pubitemid 14227492)
42. Pongnikorn S, Fongmoon D, Kasinrerk W, Limtrakul PN. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy. J Med Assoc Thai 2003;86(1):61-68. (Pubitemid 36534714)
43. Hussain BM, Geetha N, Lali V, Pandey M. Rituximab induced hypoglycemia in non-Hodgkin's lymphoma. World J Surg Oncol 2006;4:89.
44. Cicero AF, Derosa G, Gaddi A. What do herbalists suggest to diabetic patients in order to improve glycemic control? Evaluation of scientific evidence and potential risks. Acta Diabetol 2004;41(3):91-98. (Pubitemid 39304483)
45. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90(3):233-239. (Pubitemid 40576836)
46. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002;76(1):1-10. (Pubitemid 35178623)
47. Gurley BJ, Gardner SF, Hubbard MA, et al. in vivo Effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77(5):415-426. (Pubitemid 40719269)
48. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80(1):61-74. (Pubitemid 43946844)
49. Hayashi O, Katoh T, Okuwaki Y. Enhancement of antibody production in mice by dietary Spirulina platensis. J Nutr Sci Vitaminol (Tokyo) 1994;40(5):431-441. (Pubitemid 24367551)
50. Guo JJ, Wigle PR, Lammers K, Vu O. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm 2005;1(3):460-479. (Pubitemid 44061732)
51. Felter SP, Vassallo JD, Carlton BD, Daston GP. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 2006;44(4):462-475. (Pubitemid 43375122)
52. Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res 2003;63(18):5902-5908. (Pubitemid 37187491)
53. ® (trabectedin) 0.25mg and 1mg powder for concentrate for solution for infusion [package insert]. Madrid, Spain, 2009.
54. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7(4):273-282. (Pubitemid 30618491)
55. ® kit (temsirolimus) injection [package insert]. Philadelphia, PA, 2008.
56. Sandoval M, Charbonnet RM, Okuhama NN, et al. Cat's claw inhibits TNFalpha production and scavenges free radicals: Role in cytoprotection. Free Radic Biol Med 2000;29(1):71-78. (Pubitemid 30658139)
57. Gordon DW, Rosenthal G, Hart J, Sirota R, Baker AL. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA 1995;273(6):489-490.
58. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995;90(5):831-833.
59. Chen YJ, Shiao MS, Lee SS, Wang SY. Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Life Sci 1997;60(25):2349-2359.
60. Chen GZ, Chen GL, Sun T, Hsieh GC, Henshall JM. Effects of Cordyceps sinensis on murine T lymphocyte subsets. Chin Med J (Engl) 1991;104(1):4-8.
61. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004;18(19):2273-2281. (Pubitemid 39297365)
62. Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine 2001;8(1):28-30. (Pubitemid 32242089)
63. Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 2006;20(12):1046-1051.
64. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai (Angelica sinensis) to treat peri-or postmenopausal symptoms in women with breast cancer: Is it appropriate? Menopause 2005;12(6):734-740. (Pubitemid 41669126)
65. Page RL, 2nd, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999;19(7):870-876. (Pubitemid 29415843)
66. Lambert JP, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001;21(4):509-512. (Pubitemid 32275282)
67. Meijerman I, Beijnen JH, Schellens J H M. Herb-drug interactions in oncology: Focus on mechanisms of induction. Oncologist 2006;11(7):742-752. (Pubitemid 44157562)
68. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71(13):1579-1589. (Pubitemid 34808718)
69. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34(2):234-238. (Pubitemid 34028358)
70. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001;4(2):176-184. (Pubitemid 34305609)
71. Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010;79(2):154-161.
72. Azzariti A, Porcelli L, Simone GM, et al. Tyrosine kinase inhibitors and multidrug resistance proteins: Interactions and biological consequences. Cancer Chemother Pharmacol 2009;4 Jun. (article in press): doi: 10.1007/s00280-009- 1039-0.
73. Colabufo NA, Pagliarulo V, Berardi F, et al. Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins. Eur J Pharmacol 2008;601(1-3):38-42.
74. ® (bicalutamide) oral tablets [package insert]. Wilmington, DE, 2003.
75. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2007;27(9):1237-1247. (Pubitemid 47339121)
76. Heck AM, De Witt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57(13):1221-1227.
77. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14(12):841-850. (Pubitemid 40054339)
78. Taki Y, Yamazaki Y, Shimura F, Yamada S, Umegaki K. Timedependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci 2009;109(3):459-462.
79. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005;11(3):433-439. (Pubitemid 40994577)
80. Li L, Stanton JD, Tolson AH, Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009;26(4):872-882.
81. Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res 2009;60(1):68-73.
82. ® (procarbazine hydrochloride) capsules [package insert]. Gaithersburg, MD, 2004.
83. Xie JT, Mehendale SR, Li X, et al. Anti-diabetic effect of ginsenoside Re in ob/ob mice. Biochim Biophys Acta 2005;1740(3):319-325. (Pubitemid 40804743)
84. Shin HR, Kim JY, Yun TK, Morgan G, Vainio H. The cancerpreventive potential of Panax ginseng: A review of human and experimental evidence. Cancer Causes Control 2000;11(6):565-576. (Pubitemid 30342846)
85. Shader RI, Greenblatt DJ. Phenelzine and the dream machine - ramblings and reflections. J Clin Psychopharmacol 1985;5(2):65.
86. Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol 1988;8(4):235.
87. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987;7(3):201-202.
88. Bahrke MS. Comments on "Manic episode and ginseng: report of a possible case". J Clin Psychopharmacol 1997;17(2):140-141. (Pubitemid 27148326)
89. th ed. Portland, OR: Jones & Bartlett Publishers, Inc. 2005.
90. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNAexpressed cytochrome P450 enzyme catalytic activity. Life Sci 1999;65(15):PL209-214.
91. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev Esp Enferm Dig 2005;97(2):115-124. (Pubitemid 40522135)
92. Brinkhaus B, Lindner M, Schuppan D, Hahn EG. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine 2000;7(5):427-448.
93. Sakina MR, Dandiya PC. A psycho-neuropharmacological profile of Centella asiatica extract. Fitoterapia 1990;61(4):291-296. (Pubitemid 20349086)
94. Cauffield JS, Forbes HJ. Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract 1999;3(3):290-304.
95. Wijeweera P, Arnason JT, Koszycki D, Merali Z. Evaluation of anxiolytic properties of Gotukola - (Centella asiatica) extracts and asiaticoside in rat behavioral models. Phytomedicine 2006;13(9-10):668-676. (Pubitemid 44666404)
96. AIDSinfo. Paclitaxel. http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailT. aspx?MenuItem=Drug&samp;int-id=190&Search=Off&Cl assID=0&TypeID=0 [Accessed 8 August 2009].
97. Netsch MI, Gutmann H, Schmidlin CB, Aydogan C, Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006;72(6):514-520. (Pubitemid 43844678)
98. Yang SP, Raner GM. Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. Toxicol Appl Pharmacol 2005;202(2):140-150. (Pubitemid 40044828)
99. Chen L, Bondoc FY, Lee MJ, Hussin AH, Thomas PE, Yang CS. Caffeine induces cytochrome P4501A2: Induction of CYP1A2 by tea in rats. Drug Metab Dispos 1996;24(5):529-533.
100. Muto S, Fujita K, Yamazaki Y, Kamataki T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 2001;479(1-2):197-206. (Pubitemid 32695501)
101. Chow HH, Hakim IA, Vining DR, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006;15(12):2473-2476. (Pubitemid 46048307)
102. Donovan JL, Chavin KD, Devane CL, et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32(9):906-908. (Pubitemid 39096049)
103. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acidbased proteasome inhibitors. Blood 2009;113(23):5927-5937.
104. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33(4):426-428. (Pubitemid 29215809)
105. Kang WS, Chung KH, Chung JH, et al. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase. J Cardiovasc Pharmacol 2001;38(6):875-884.
106. Sagesaka-Mitane Y, Miwa M, Okada S. Platelet aggregation inhibitors in hot water extract of green tea. Chem Pharm Bull (Tokyo) 1990;38(3):790-793. (Pubitemid 20316821)
107. Son DJ, Cho MR, Jin YR, et al. Antiplatelet effect of green tea catechins: A possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids 2004;71(1):25-31.
108. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009;65(4):331-341.
109. American Society of Health-System Pharmacists. AHFS Drug Information. 2007 ed. Bethesda, MD, American Society of Health-System Pharmacists Inc. 2007.
110. Lee CK, Park KK, Lim SS, Park J H Y, Chung WY. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull 2007;30(11):2191-2195. (Pubitemid 350097049)
111. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 1994;23(2):359-377. (Pubitemid 24191810)
112. Sundaram MB, Swaminathan R. Total body potassium depletion and severe myopathy due to chronic liquorice ingestion. Postgrad Med J 1981;57(663):48-49. (Pubitemid 11141967)
113. Tamir S, Eizenberg M, Somjen D, et al. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res 2000;60(20):5704-5709.
114. Kent UM, Aviram M, Rosenblat M, Hollenberg PF. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002;30(6):709-715. (Pubitemid 34579106)
115. Mu Y, Zhang J, Zhang S, et al. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 2006;316(3):1369-1377. (Pubitemid 43345314)
116. Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P, Cantelli-Forti G. Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 1999;145(1-2):35-42. (Pubitemid 29459067)
117. Paolini M, Pozzetti L, Sapone A, Cantelli-Forti G. Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 1998;62(6):571-582. (Pubitemid 28050076)
118. Shon JH, Park JY, Kim KA, Cha IJ, Chun BH, Shin JG. Effect of licorice (radix glycyrrhizae) on the pharmacokinetics (PK) and pharmacodynamics (PD) of midazolam in healthy subjects. Clin Pharmacol Ther 2001;69(2):P78. (Pubitemid 33787027)
119. Gurley BJ, Gardner SF, Hubbard MA, et al. in vivo Assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76(5):428-440. (Pubitemid 39469867)
120. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000;86(6):250-256. (Pubitemid 30413400)
121. Dresser GK, Wacher V, Wong S, Wong HT, Bailey DG. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002;72(3):247-255.
122. Shulman KI, Walker SE. Refining the MAOI diet: Tyramine content of pizzas and soy products. J Clin Psychiatry 1999;60(3):191-193. (Pubitemid 29168693)
123. de Lemos ML. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann Pharmacother 2001;35(9):1118-1121. (Pubitemid 32880033)
124. Jones JL, Daley BJ, Enderson BL, Zhou J-R, Karlstad MD. Genistein inhibits tamoxifen effects on cell proliferation and cell cycle arrest in T47D breast cancer cells. Am Surg 2002;68(6):575-577. (Pubitemid 44897068)
125. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62(9):2474-2477. (Pubitemid 34462720)
126. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998;31(Suppl 1):16-21.
127. Singer A, Wonnemann M, Müller WE. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J Pharmacol Exp Ther 1999;290(3):1363-1368. (Pubitemid 29400281)
128. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's Wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76(4):323-329. (Pubitemid 39313122)
129. ® (erlotinib) tablets [package insert]. Melville, NY and South San Francisco, CA, 2004.
130. ® (gefitinib) tablets [package insert]. Wilmington, DE, 2005.
131. ® (lapatinib) tablets [package insert]. Research Triangle Park, NC, 2007.
132. Mathijssen R H J, Verweij J, Bruijn PD, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94(16):1247-1249. (Pubitemid 34993875)
133. ™ kit (ixabepilone) for injection [package insert]. Princeton, NJ, 2007.
134. Lundgren S, Lonning PE, Aakvaag A, Kvinnsland S. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1990;27(2):101-105.
135. Kobayashi K, Mimura N, Fujii H, et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 2000;6(8):3297-3303. (Pubitemid 30637760)
136. Halpenny O, Bye A, Cranny A, Feely J, Daly PA. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate. Med Oncol Tumor Pharmacother 1990;7(4):241-247. (Pubitemid 20343623)
137. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005;31(2):139-151.
138. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: A randomized controlled trial. Br J Clin Pharmacol 2003;56(6):683-690. (Pubitemid 37491722)
139. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003;55(1):112-113. (Pubitemid 36110847)
140. Wilbur K, Ensom MH. Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants. Clin Pharmacokinet 2000;38(4):355-365. (Pubitemid 30229471)
141. Hall SD, Wang Z, Huang SM, et al. The interaction between St. John's wort and an oral contraceptive. Clin Pharmacol Ther 2003;74(6):525-535. (Pubitemid 37521996)
142. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. John's Wort: Effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67(5):451-457. (Pubitemid 30327483)
143. Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report. J Clin Oncol 1998;16(6):2188-2194. (Pubitemid 28265057)
144. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998;4(3):783-789. (Pubitemid 28193579)
145. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999;17(5):1516-1525. (Pubitemid 29220860)
146. Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St. John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008;153(7):1579-1586. (Pubitemid 351481511)
147. Schwarz UI, Hanso H, Oertel R, et al. Induction of intestinal Pglycoprotein by St. John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 2007;81(5):669-678. (Pubitemid 46625125)
148. Dürr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68(6):598-604. (Pubitemid 32059985)
149. Bove GM. Acute neuropathy after exposure to sun in a patient treated with St. John's Wort. Lancet 1998;352(9134):1121-1122. (Pubitemid 28448527)
150. Ernst E, Rand JI, Barnes J, Stevinson C. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998;54(8):589-594. (Pubitemid 28531418)
151. ® (thalidomide) capsules [package insert]. Summit, NJ, 2003.
152. Holme SA, Roberts DL. Erythroderma associated with St. John's wort. Br J Dermatol 2000;143(5):1127-1128.
153. Golsch S, Vocks E, Rakoski J, Brockow K, Ring J. Reversible increase in photosensitivity to UV-B caused by St. John's wort extract. Hautarzt 1997;48(4):249-252. (Pubitemid 27225919)
154. Lane-Brown MM. Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum). Med J Aust 2000;172(6):302. (Pubitemid 30185036)
155. Gulick RM, McAuliffe V, Holden-Wiltse J, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999;130(6):510-514. (Pubitemid 29135804)
156. Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001;45(2):517-524. (Pubitemid 32105289)
157. Brockmöller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997;30(Suppl 2):94-101.
158. Schempp CM. Single-dose and steady-state administration of Hypericum perforatum extract (St John's wort) does not influence skin sensitivity to UV radiation, visible light, and solar-simulated radiation. Arch Dermatol 2001;137(4):512-513. (Pubitemid 32319861)
159. Schempp CM, Pelz K, Wittmer A, Schopf E, Simon JC. Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet 1999;353(9170):2129. (Pubitemid 29278489)
160. Bernd A, Simon S, Ramirez Bosca A, et al. Phototoxic effects of Hypericum extract in cultures of human keratinocytes compared with those of psoralen. Photochem Photobiol 1999;69(2):218-221. (Pubitemid 129606908)
161. ® (temoporfin) 4mg/ml solution for injection [package insert]. Dublin, Ireland, 2005.
162. ® (porfimer sodium) injection powder for solution [package insert]. Birmingham, AL, 2005.
163. Ligand Pharmaceuticals Inc. Panretin gel 0.1% (alitretinoin) [package insert]. San Diego, CA, 2001.
164. ® (tretinoin) 10mg capsules [package insert]. Nutley, NJ, 2008.
165. Lefebvre T, Foster BC, Drouin CE, Krantis A, Livesey JF, Jordan SA. in vitro Activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci 2004;7(2):265-273. (Pubitemid 41528901)
166. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32(12):1333-1336. (Pubitemid 39564550)
167. Krivoy N, Pavlotzky E, Chrubasik S, Eisenberg E, Brook G. Effect of salicis cortex extract on human platelet aggregation. Planta Med 2001;67(3):209-212. (Pubitemid 32304188)
168. Clauson KA, Santamarina ML, Buettner CM, Cauffield JS. Evaluation of presence of aspirin-related warnings with willow bark. Ann Pharmacother 2005;39(7-8):1234-1237. (Pubitemid 40943175)
169. Yap KY, Chan SY, Chan YW, Lim CS. Overview on the analytical tools for quality control of natural product-based supplements: A case study of ginseng. Assay Drug Dev Technol 2005;3(6):683-699. (Pubitemid 43256959)
170. Jung YD, Ellis LM. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 2001;82(6):309-316. (Pubitemid 34063029)
171. Billinsky JL, Marcoux MR, Krol ES. Oxidation of the lignan nordihydroguaiaretic acid. Chem Res Toxicol 2007;20(9):1352-1358. (Pubitemid 47548303)
172. Kretzschmar G, Zierau O, Wober J, Tischer S, Metz P, Vollmer G. Prenylation has a compound specific effect on the estrogenicity of naringenin and genistein. J Steroid Biochem Mol Biol 2009;4 September (in press): doi: 10.1016/j.jsbmb.2009.08.005.
173. Jaracz S, Malik S, Nakanishi K. Isolation of ginkgolides A, B, C, J and bilobalide from G. biloba extracts. Phytochemistry 2004;65(21):2897-2902. (Pubitemid 40292122)
174. Wang CZ, Aung HH, Zhang B, et al. Chemopreventive effects of heat-processed Panax quinquefolius root on human breast cancer cells. Anticancer Res 2008;28(5 A):2545-2551.
175. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of ginseng use with survival and quality of life among breast cancer patients. Am J Epidemiol 2006;163(7):645-653.
176. Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: A case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev 1995;4(4):401-408.
177. Yun TK, Choi SY, Yun HY. Epidemiological study on cancer prevention by ginseng: Are all kinds of cancers preventable by ginseng? J Korean Med Sci 2001;16 Suppl: S19-S27.
178. Davydov M, Krikorian AD. Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: A closer look. J Ethnopharmacol 2000;72(3):345-393.
179. Tang FY, Chiang EP, Chung JG, Lee HZ, Hsu CY. S-Allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. J Nutr Biochem 2009;20(12):1013-1020.
180. Seki T, Hosono T, Hosono-Fukao T, et al. Anticancer effects of diallyl trisulfide derived from garlic. Asia Pac J Clin Nutr 2008;17(Suppl 1):249-252.
181. Wang EJ, Barecki-Roach M, Johnson WW. Elevation of Pglycoprotein function by a catechin in green tea. Biochem Biophys Res Commun 2002;297(2):412-418. (Pubitemid 35216187)
182. Myhill, P. R., Driscoll, W. J.: US20097579026 (2009).
183. Rangel, O., Angel, J.: US20097553501 (2009).
184. Managoli, N. B.: US20087390514 (2008).
185. Managoli, N. B.: US20087344738 (2008).
186. Hsieh, C. F.: US20097527812 (2009).
187. Djang, A. H. K.: US20016168795 (2001).
188. Myhill, P. R., Driscoll, W. J.: US20087384655 (2008).
189. Myhill, P. R., Driscoll, W. J.: US20077241461 (2007).
190. Zhang HQ, Lin AP, Sun Y, Deng YM. Chemo-and radioprotective effects of polysaccharide of Spirulina platensis on hemopoietic system of mice and dogs. Acta Pharmacol Sin 2001;22(12):1121-1124.
191. Mathew B, Sankaranarayanan R, Nair PP, et al. Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutr Cancer 1995;24(2):197-202.
192. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24(18):2932-2947. (Pubitemid 46630595)
193. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 2007;18(2):233-240. (Pubitemid 46323087)
194. Ka H, Park HJ, Jung HJ, et al. Cinnamaldehyde induces apoptosis by ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells. Cancer Lett 2003;196(2):143-152. (Pubitemid 36830893)
195. Pavani M, Fones E, Oksenberg D, et al. Inhibition of tumoral cell respiration and growth by nordihydroguaiaretic acid. Biochem Pharmacol 1994;48(10):1935-1942. (Pubitemid 24355022)
196. Takahashi T, Takasuka N, Iigo M, et al. Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin E2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development. Cancer Sci 2004;95(5):448-453. (Pubitemid 38832690)
197. Cheng, Y.-C., Liu, S.-H.: US20097534455 (2009).
198. Cheng, Y.-C., Liu, S.-H.: US20067025993 (2006).
199. Kuok, K. Y., Ly, H.: US20046790464 (2004).
200. Li, H.: US20056911221 (2005).
201. Kohno H, Tanaka T, Kawabata K, et al. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethaneinduced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101(5):461-468.
202. Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate 2002;53(3):211-217. (Pubitemid 35266181)
203. Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anticancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004;11(2):493-499.
204. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007;6(2):130-145. (Pubitemid 46871840)
205. Verschoyle RD, Greaves P, Patel K, et al. Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: Relationship with silibinin levels. Eur J Cancer 2008;44(6):898-906.
206. Kvasnicka F, Biba B, Sevcik R, Voldrich M, Kratka J. Analysis of the active components of silymarin. J Chromatogr A 2003;990(1-2):239-245. (Pubitemid 36293880)
207. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996;11(1):55-62. (Pubitemid 26038465)
208. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA 2005;294(12):1493-1504. (Pubitemid 41362686)
209. Yan L, Spitznagel EL. Soy consumption and prostate cancer risk in men: A revisit of a meta-analysis. Am J Clin Nutr 2009;89(4):1155-1163.
210. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003;95(15):1158-1164. (Pubitemid 37045394)
211. Cline JM, Hughes Jr CL. Phytochemicals for the prevention of breast and endometrial cancer. Cancer Treat Res 1998;94:107-134.
212. Lamartiniere CA. Protection against breast cancer with genistein: A component of soy. Am J Clin Nutr 2000;71(Suppl 6):1705S-1707S.
213. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006;98(7):459-471.
214. Cho WC, Leung KN. in vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol 2007;113(1):132-141. (Pubitemid 47077858)
215. Cho WC, Leung KN. in vitro and in vivo Anti-tumor effects of Astragalus membranaceus. Cancer Lett 2007;252(1):43-54. (Pubitemid 46734552)
216. Auyeung KK, Cho CH, Ko JK. A novel anticancer effect of Astragalus saponins: Transcriptional activation of NSAIDactivated gene. Int J Cancer 2009;125(5):1082-1091.
217. Luo Z, Zhong L, Han X, Wang H, Zhong J, Xuan Z. Astragalus membranaceus prevents daunorubicin-induced apoptosis of cultured neonatal cardiomyocytes: Role of free radical effect of Astragalus membranaceus on daunorubicin cardiotoxicity. Phytother Res 2009;23(6):761-767.
218. Lee, C.-Y.: US20067005146 (2006).
219. Kohno H, Yasui Y, Suzuki R, Hosokawa M, Miyashita K, Tanaka T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. Int J Cancer 2004;110(6):896-901. (Pubitemid 38758517)
220. Grossmann ME, Mizuno NK, Dammen ML, Schuster T, Ray A, Cleary MP. Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. Cancer Prev Res (Phila Pa) 2009;2(10):879-886.
221. Lee-Huang S, Huang PL, Chen HC, Bourinbaiar A, Huang HI, Kung HF. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995;161(2):151-156.
222. Attele AS, Wu JA, Yuan CS. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 1999;58(11):1685-1693. (Pubitemid 29505408)
223. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. Psychooncology 2009;27 July [in press]: doi: 10.1002/pon. 1615.
224. Cohen PR. Primary alopecia neoplastica versus secondary alopecia neoplastica: A new classification for neoplasm-associated scalp hair loss. J Cutan Pathol 2009;36(8):917-918.
225. Schulz C, Bielfeldt S, Reimann J. Fenugreek micronutrients: Efficacy of a food supplement against hair loss. Kosmetische Medizin 2006;27(4):176-179. (Pubitemid 44768545)
226. Schnell FM. Chemotherapy-induced nausea and vomiting: The importance of acute antiemetic control. Oncologist 2003;8(2):187-198. (Pubitemid 36428284)
227. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer 2009;23 August (in press): doi: 10.1007/s00520-009-0723-2.
228. Westfall RE. Use of anti-emetic herbs in pregnancy: Women's choices, and the question of safety and efficacy. Complement Ther Nurs Midwifery 2004;10(1):30-36. (Pubitemid 38159751)
229. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: A systematic review of randomized clinical trials. Br J Anaesth 2000;84(3):367-371. (Pubitemid 30114135)
230. Betz O, Kranke P, Geldner G, Wulf H, Eberhart LH. Is ginger clinically relevant antiemetic? A systematic review of randomized controlled trials. Forsch Komplementarmed Klass Naturheilkd 2005;12(1):14-23 (abstract). (Pubitemid 40529184)
231. Tate S. Peppermint oil: a treatment for postoperative nausea. J Adv Nurs 1997;26(3):543-549. (Pubitemid 127451637)
232. Wilkinson JM. What do we know about herbal morning sickness treatments? A literature survey. Midwifery 2000;16(3):224-228.
233. Anderson LA, Gross JB. Aromatherapy with peppermint, isopropyl alcohol, or placebo is equally effective in relieving postoperative nausea. J Perianesth Nurs 2004;19(1):29-35. (Pubitemid 38199828)
234. Jung ES, Lee BS. Effects of aroma oil inhalation on nausea vomiting and anorexia in cancer patients receiving chemotherapy. J Korean Acad Adult Nurs 2004;16(1):135-145 (abstract).
235. Vail III, W. B., Vail, M. L.: US20087344740 (2008).
236. Islam MS, Choi H. Comparative effects of dietary ginger (Zingiber officinale) and garlic (Allium sativum) investigated in a type 2 diabetes model of rats. J Med Food 2008;11(1):152-159. (Pubitemid 351450508)
237. Al-Amin ZM, Thomson M, Al-Qattan KK, Peltonen-Shalaby R, Ali M. Anti-diabetic and hypolipidaemic properties of ginger (Zingiber officinale) in streptozotocin-induced diabetic rats. Br J Nutr 2006;96(4):660-666. (Pubitemid 46470189)
238. Ojewole JA. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of Zingiber officinale (Roscoe) rhizomes (Zingiberaceae) in mice and rats. Phytother Res 2006;20(9):764-772. (Pubitemid 44408657)
239. Sekiya K, Ohtani A, Kusano S. Enhancement of insulin sensitivity in adipocytes by ginger. Biofactors 2004;22(1-4):153-156.
240. Sindrup SH, Madsen C, Bach FW, Gram LF, Jensen TS. St. John's wort has no effect on pain in polyneuropathy. Pain 2001;91(3):361-365. (Pubitemid 32241158)
241. Linde K, Berner MM, Kriston L. St. John's wort for major depression. Cochrane Database Syst Rev 2008(4):CD000448.
242. Laakmann G, Schule C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998;31(Suppl 1):54-59. (Pubitemid 28294226)
243. Boiy A, Roelandts R, van den Oord J, de Witte PA. Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin. Br J Dermatol 2008;158(2):360-369.
244. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11(4):294-329. (Pubitemid 46037130)
245. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebocontrolled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 1997;15(8):2974-2980. (Pubitemid 27330026)
246. Mori A, Lehmann S, O'Kelly J, et al. Capsaicin, a component of red peppers, inhibits the growth of androgen-independent, p53 mutant prostate cancer cells. Cancer Res 2006;66(6):3222-3229.
247. Zhang J, Nagasaki M, Tanaka Y, Morikawa S. Capsaicin inhibits growth of adult T-cell leukemia cells. Leuk Res 2003;27(3):275-283. (Pubitemid 36132118)
248. Schmid B, Ludtke R, Selbmann HK, et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res 2001;15(4):344-350. (Pubitemid 32613105)
249. Khayyal MT, El-Ghazaly MA, Abdallah DM, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the anti-inflammatory effect of a standardized willow bark extract. Arzneimittelforschung 2005;55(11):677-687. (Pubitemid 41756051)
250. Schmid B, Kotter I, Heide L. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur J Clin Pharmacol 2001;57(5):387-391. (Pubitemid 33787189)
251. Fiebich BL, Appel K. Anti-inflammatory effects of willow bark extract. Clin Pharmacol Ther 2003;74(1):96.
252. Staiger C. Comfrey: ancient and modern uses. Pharm J 2007;279:732.
253. Mei N, Guo L, Zhang L, et al. Analysis of gene expression changes in relation to toxicity and tumorigenesis in the livers of Big Blue transgenic rats fed comfrey (Symphytum officinale). BMC Bioinform 2006;7(Suppl 2):S16.
254. Mei N, Guo L, Fu PP, Heflich RH, Chen T. Mutagenicity of comfrey (Symphytum Officinale) in rat liver. Br J Cancer 2005;92(5):873-875. (Pubitemid 40462632)
255. Hirono I, Mori H, Haga M. Carcinogenic activity of Symphytum officinale. J Natl Cancer Inst 1978;61(3):865-869. (Pubitemid 9029122)
256. Stickel F, Seitz HK. The efficacy and safety of comfrey. Public Health Nutr 2000;3(4 A):501-508. (Pubitemid 32095588)
257. Weston CF, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987;295(6591):183. (Pubitemid 17101024)
258. Sandoval M, Okuhama NN, Zhang XJ, et al. Anti-inflammatory and antioxidant activities of cat's claw (Uncaria tomentosa and Uncaria guianensis) are independent of their alkaloid content. Phytomedicine 2002;9(4):325-337. (Pubitemid 34712504)
259. Huang TH, Tran VH, Duke RK, et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol 2006;104(1-2):149-155. (Pubitemid 43234097)
260. Lanhers MC, Fleurentin J, Mortier F, Vinche A, Younos C. Antiinflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 1992;58(2):117-123.
261. Baghdikian B, Lanhers MC, Fleurentin J, et al. An analytical study, anti-inflammatory and analgesic effects of Harpagophytum procumbens and Harpagophytum zeyheri. Planta Med 1997;63(2):171-176. (Pubitemid 27196089)
262. Keplinger K, Laus G, Wurm M, Dierich MP, Teppner H. Uncaria tomentosa (Willd.) DC. - ethnomedicinal use and new pharmacological, toxicological and botanical results. J Ethnopharmacol 1999;64(1):23-34. (Pubitemid 29059552)
263. Villasenor IM. Bioactivities of iridoids. Antiinflamm Antiallergy Agents Med Chem 2007;6(4):307-314.
264. ® (paclitaxel protein-bound particles) for injectable suspension [package insert]. Los Angeles, CA, 2007.
265. ® (vincristine sulfate injection USP) [package insert]. Irvine, CA, 2003.
266. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56(6):1296-1302. (Pubitemid 26080972)
267. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54(2):386-392. (Pubitemid 24053174)
268. Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53(21):5121-5126. (Pubitemid 23333376)
269. Zhou XJ, Placidi M, Rahmani R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 1994;14(3 A):1017-1022. (Pubitemid 24272560)
270. Bedford Laboratories. Vinblastine sulfate for injection USP [package insert]. Bedford, OH, 2001.
271. Sicor Pharmaceuticals Inc. Vinorelbine tartrate injection [package insert]. Irvine, CA, 2003.
272. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10(4):1289-1298. (Pubitemid 38365219)
273. Goel S, Cohen M, Çömezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: A first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 2008;14(9):2701-2709.
274. Li H, Gong X, Zhang L, et al. Madecassoside attenuates inflammatory response on collagen-induced arthritis in DBA/1 mice. Phytomedicine 2009;16(6-7):538-546.
275. Awang D V C. Gotu kola. Can Pharm J 1998;131(7):42-46. (Pubitemid 28501320)
276. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin 2007;25(4):1035-1071. (Pubitemid 47610811)
277. Redeker NS, Lev EL, Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000;14(4):275-290.
278. Kennedy DO, Haskell CF, Robertson B, et al. Improved cognitive performance and mental fatigue following a multi-vitamin and mineral supplement with added guarana (Paullinia cupana). Appetite 2008;50(2-3):506-513.
279. da Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. J Altern Complement Med 2009;15(4):431-433.
280. Heck CI, de Mejia EG. Yerba Mate Tea (Ilex paraguariensis): A comprehensive review on chemistry, health implications, and technological considerations. J Food Sci 2007;72(9):R138-R151. (Pubitemid 350150695)
281. Anesini C, Ferraro G, Filip R. Peroxidase-like activity of Ilex paraguariensis. Food Chem 2006;97(3):459-464. (Pubitemid 43003749)
282. Bracesco N, Dell M, Rocha A, et al. Antioxidant activity of a botanical extract preparation of Ilex paraguariensis: Prevention of DNA double-strand breaks in Saccharomyces cerevisiae and human low-density lipoprotein oxidation. J Altern Complement Med 2003;9(3):379-387. (Pubitemid 36628987)
283. Ramirez-Mares MV, Chandra S, de Mejia EG. In vitro chemopreventive activity of Camellia sinensis, Ilex paraguariensis and Ardisia compressa tea extracts and selected polyphenols. Mutat Res 2004;554(1-2):53-65. (Pubitemid 39144391)
284. Loria D, Barrios E, Zanetti R. Cancer and yerba mate consumption: A review of possible associations. Rev Panam Salud Publica 2009;25(6):530-539.
285. Bates MN, Hopenhayn C, Rey OA, Moore LE. Bladder cancer and mate consumption in Argentina: A case-control study. Cancer Lett 2007;246(1-2):268- 273. (Pubitemid 44959398)
286. Goldenberg D, Golz A, Joachims HZ. The beverage mate: A risk factor for cancer of the head and neck. Head Neck 2003;25(7):595-601. (Pubitemid 36740505)
287. Kamangar F, Schantz MM, Abnet CC, Fagundes RB, Dawsey SM. High levels of carcinogenic polycyclic aromatic hydrocarbons in mate drinks. Cancer Epidemiol Biomarkers Prev 2008;17(5):1262-1268.
288. Ruhlen RL, Sun GY, Sauter ER. Black cohosh: insights into its mechanism (s) of action. Integr Med Insights 2008;3:21-32.
289. Einbond, L. S., Weinstein, I. B.: US20087407675 (2008).
290. Carroll DG. Nonhormonal therapies for hot flashes in menopause. Am Fam Physician 2006;73(3):457-464.
291. Tsai NM, Lin SZ, Lee CC, et al. The antitumor effects of Angelica sinensis on malignant brain tumors in vitro and in vivo. Clin Cancer Res 2005;11(9):3475-3484.
292. Shang P, Qian AR, Yang TH, et al. Experimental study of antitumor effects of polysaccharides from Angelica sinensis. World J Gastroenterol 2003;9(9):1963-1967. (Pubitemid 37168422)
293. Hauns B, Haring B, Kohler S, Mross K, Unger C. Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. Phytother Res 2001;15(1):34-38. (Pubitemid 32155107)
294. Umegaki K, Taki Y, Endoh K, et al. Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J Pharm Pharmacol 2007;59(6):871-877. (Pubitemid 47051100)
295. Benke D, Barberis A, Kopp S, et al. GABA A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology 2009;56(1):174-181.
296. Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med 2007;7:28.
297. Laengler A, Spix C, Seifert G, Gottschling S, Graf N, Kaatsch P. Complementary and alternative treatment methods in children with cancer: A population-based retrospective survey on the prevalence of use in Germany. Eur J Cancer 2008;44(15):2233-2240.
298. Yang C, Chien LY, Tai CJ. Use of complementary and alternative medicine among patients with cancer receiving outpatient chemotherapy in Taiwan. J Altern Complement Med 2008;14(4):413-416. (Pubitemid 351693511)
299. Shih V, Chiang JY, Chan A. Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. Ann Oncol 2009;20(4):752-757.
300. Kristoffersen AE, Fønnebø V, Norheim AJ. Do cancer patients with a poor prognosis use complementary and alternative medicine more often than others? J Altern Complement Med 2009;15(1):35-40.
301. Zhou S-F, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008;9(8):738-784.
302. Shai RM, Reichardt J K V, Chen TC. Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. Future Oncol 2008;4(4):525-534.
303. American Association for Cancer Research Human Epigenome Task Force, European Union, Network of Excellence, Scientific Advisory Board. Moving AHEAD with an international human epigenome project. Nature 2008;454(7205):711-715.
304. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116(3):496-526. (Pubitemid 350116943)
305. Szyf M. Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2004;2(4):357-377. (Pubitemid 39561840)